At baseline (enrolment visit), 6439 men (mean age 66 years) completed the IPSS BQ and the BPH-II. The mean ( SD ) score of the IPSS BQ was 2.5 (1.4) and of the BPH-II was 2.8 (2.8). Based on responses to the BPH-II, at least half the men reported that their urinary symptoms were associated with physical discomfort, worry about their health, and bothersomeness. The IPSS BQ score was significantly correlated ( P < 0.001) with the BPH-II ( r = 0.68) and each of its four questions (physical discomfort, r = 0.52; worry about health, r = 0.53; bothersomeness of trouble with urination, r = 0.67; and time kept from usual activities, r = 0.44).
CONCLUSIONS
The IPSS BQ score has a strong and positive correlation with the BPH-II among men enrolled in the BPH Registry. The IPSS BQ is a convenient tool for assessing disease-specific quality of life when determining treatment strategies and evaluating treatment outcomes in men with BPH.
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OBJECTIVE
To evaluate the association between the International Prostate Symptom Score (IPSS) bother question (BQ) and a validated diseasespecific quality-of-life questionnaire, the Benign Prostatic Hyperplasia (BPH) Impact Index (BPH-II), using the BPH Registry and Patient Survey database.
PATIENTS AND METHODS
The BPH Registry and Patient Survey is a multicentre, longitudinal, observational database of management practices and patient outcomes in a population of patients
INTRODUCTION
BPH is a common health problem in ageing men, affecting 50-80% of men aged 50-80 years [1] . Many men with BPH develop moderate-to-severe LUTS, including a weak urinary stream, hesitancy during urination, straining to initiate urination, increased frequency of urination, nocturia, and a sensation of incomplete bladder emptying after urination, that can be bothersome and compromise their quality of life (QoL) [2, 3] . The bother associated with LUTS/BPH is the main reason that men seek treatment, and a key decision point in the diagnosis and treatment algorithm of the AUA 2003 guidelines on managing BPH [4] . In general, watchful waiting is the standard recommendation for men with BPH and mild or moderate-to-severe LUTS that are not bothersome, whereas watchful waiting, medical therapy, e.g. α 1 -adrenergic blockers (ABs), 5 α -reductase inhibitors (5ARIs), and AB plus 5ARI combined, minimally invasive therapy, or surgical therapy are recommended management options for men with bothersome moderate-to-severe LUTS associated with BPH [4].
The seven-item AUA Symptom Index, developed and psychometrically validated by an AUA Measurement Committee in 1992, reliably assesses the severity of LUTS and is responsive to changes in treatment [5] . The eight-item IPSS, which uses the same seven questions assessing LUTS severity as the AUA Symptom Index, plus an eighth diseasespecific QoL question that assesses the bother associated with LUTS, was adopted by the WHO in 1993 [6] . The IPSS bother question (BQ) is the most commonly used measure of QoL in the evaluation of men with BPH [7] . Various studies have shown the reliability, validity and sensitivity of the IPSS BQ [5, 8, 9] and the strong positive association between LUTS severity and the IPSS BQ score for men from different countries and cultural backgrounds [2,9-14]. Thus, it has been suggested that the IPSS BQ is a simple and reliable tool for assessing treatment outcomes in men with bothersome LUTS/BPH [15] . To further test this hypothesis, we evaluated the association between the IPSS BQ and a validated disease-specific QoL instrument, the BPH Impact Index (BPH-II) [8], using baseline data from the BPH Registry and Patient Survey.
PATIENTS AND METHODS
The BPH Registry and Patient Survey is a prospective, multicentre, longitudinal, observational disease registry designed to examine patient characteristics and outcomes and physician management practices in men with LUTS/BPH in the USA who are managed with watchful waiting or pharmacotherapy by urologists or primary-care providers. The registry, which was sponsored by SanofiAventis, was designed and developed by a 20-member Steering Committee composed of urologists, primary-care physicians, psychologists and a biostatistician. A full description of the design of the registry was published previously [16] . In brief, men with LUTS/BPH were eligible for enrolment if they provided consent and were: presently/ recently treated with approved prescription medications for the symptoms of BPH, untreated (i.e. managed with watchful waiting or newly diagnosed), or currently taking botanical products. Exclusion criteria included lower urinary tract disease or carcinoma, carcinoma of the prostate, bladder or kidney, previous prostate surgery or minimally invasive procedure, isolated bladder neck disease or urethral stenosis/strictures, gross haematuria, acute urinary retention, neurological disease affecting urinary function, active kidney or liver disease, and use of LHRH analogues or antiandrogens.
At the baseline visit, men completed a demographic questionnaire and various other questionnaires, including the IPSS BQ [5] and the four-item BPH-II [8]. The IPSS BQ ('If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?') had scores of 0 (delighted), 1 (pleased), 2 (mostly satisfied), 3 (mixed about equally satisfied and dissatisfied), 5 (mostly dissatisfied), 5 (unhappy), and 6 (terrible), with higher scores indicating worse QoL. The four questions of the BPH-II are: (i) Over the past month, how much physical discomfort did any urinary problem cause you?; (ii) Over the past month, how much did you worry about your health because of any urinary problems?; (iii) Overall, how bothersome has any trouble with urination been during the past month?; and (iv) Over the past month, how much time has any urinary problem kept you from the kinds of things you would usually do? For the BPH Registry, each question of the BPH-II had scores of 0 (none/not at all), 1 (only a little/ bothers me a little), 2 (some/bothers me some), and 3 (a lot/all of the time), with the total score calculated as the sum of the scores of the individual questions. Therefore, for the BPH Registry, the total score of the BPH-II was 0-12, with a higher score indicating worse QoL. Investigators collected information on disease history, clinical history, relevant concomitant medications, laboratory data, vital signs, and common complaints associated with BPH treatment.
Men enrolled in the BPH Registry who completed the IPSS BQ and the BPH-II at the baseline visit were identified. The association between the IPSS BQ and the BPH-II was assessed using Spearman rank correlation.
RESULTS
Of 6909 patients enrolled in the BPH Registry by urologists (4537 patients) and primarycare physicians (2372 patients) at 402 sites in the USA, 6439 (93%) completed both the IPSS BQ and the BPH-II at baseline (enrolment visit). The baseline demographics and clinical characteristics of these 6439 patients (Table 1) were comparable with those of the entire cohort of enrolled men. The median (range) age of the 6439 men was 67 (30-90) years, with 3028 (47%) not treated for their BPH before enrolment in the BPH (4919) 1.8
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Registry and 3213 (50%) treated with AB monotherapy, 5ARI monotherapy, AB + 5ARI combined therapy, or anticholinergics before enrolment. The remaining 198 (3%) men were treated with other medications or their BPH management data were not available.
The mean ( SD ) scores of the IPSS BQ and the BPH-II at baseline are listed in Table 2 . Based on responses to the four questions of the BPH-II, most of the 6439 men with BPH reported that during the past month their urinary problems were associated with physical discomfort (3206, 50%), worry about their health (3194, 50%), and bothersomeness (4104, 64%) (Fig. 1) . Only 1610 (26%) of the 6439 men reported that any urinary problem kept them from doing their usual activities. The IPSS BQ score was significantly ( P < 0.001) and positively correlated with the total score and the score for each of the four questions of the BPH-II (Table 3 ). The strongest correlations were between the IPSS BQ and question 3 (bothersomeness of trouble with urination, r = 0.67) and the total score of the BPH-II ( r = 0.68, Table 3 ).
DISCUSSION
In men with LUTS/BPH who were enrolled in the BPH Registry, the IPSS BQ has a significant and strong positive correlation with the BPH-II [8], a validated disease-specific measure of QoL that is used as a measure of treatment outcomes in men with symptomatic BPH. The present results confirm a previous report of a strong positive association between the IPSS BQ score and the BPH-II ( r = 0.62) in 4800 men, aged 40-79 years, surveyed in the UrEpik study [17] , and further support the hypothesis that the IPSS BQ is a simple and valid measure that can be useful for assessing treatment outcomes in men with symptomatic BPH [15] . Preliminary data from the BPH Registry database indicated that the IPSS BQ score was only weakly correlated with the Short Form-12, a generic QoL questionnaire. Using baseline data from 589 men enrolled during the first 3 months of the BPH Registry, the Pearson product-moment correlation coefficients for the IPSS BQ score with the Short Form-12 physical component summary score and the mental component summary score were − 0.12 and − 0.18, respectively [18] . These data suggested that the generic Short Form-12 might not adequately measure the bother associated with LUTS/BPH, confirming previous reports [7, 19, 20] .
The bothersomeness and impact of LUTS on QoL is the main reason why men seek treatment for BPH [4, 21, 22] . The current AUA guideline on the management of BPH, issued in 2003, states that the impact of LUTS/BPH on a patient's QoL, especially the bothersomeness of LUTS, should be the primary consideration in treatment decisions and in assessments of treatment response and disease progression [4] . Although various validated QoL instruments have been used to assess disease-specific QoL in men with LUTS/BPH, the IPSS BQ is the easiest to administer and the most widely accepted and used [7] . The IPSS BQ score has been used extensively to assess disease-specific QoL in placebo-controlled clinical trials evaluating pharmacotherapy for treating BPH. In the single-arm weighted average of all studies evaluating ABs, 5ARIs, combined therapy, or controls conducted by the AUA and used as a basis for the 2003 guideline, the IPSS BQ score improved (decreased) from baseline twice as much with ABs as with placebo, twice as much with combined therapy as with placebo, and the same with 5ARIs as with placebo in studies of 3-9 months' duration [23] . These results suggest that ABs improve QoL more than 5ARIs, with AB plus 5ARI therapy providing no further improvement than AB monotherapy. Although the BPH-II was used to assess QoL in fewer studies of 3-9 months' duration than the IPSS BQ in the AUA single-arm weighted analysis, the overall trends in improvements in QoL for different pharmacotherapies, as assessed with the BPH-II, were comparable with those assessed with the IPSS BQ [23] . [24] [25] [26] [27] and between the IPSS BQ score and other measures of LUTS bother [17, 24] . A recent study of a visual analogue scale version of the IPSS and IPSS BQ reported a significant test-retest reliability of the original IPSS BQ score in both healthy men ( r = 0.91) and men with LUTS ( r = 0.67) [26] . Because the IPSS BQ score is directly related to LUTS severity and is highly correlated with other disease-specific QoL measures, the IPSS BQ score represents a valuable tool for assessing treatment outcomes in men with LUTS/BPH. Just as the assessment of LUTS severity in men with BPH was standardized with the IPSS, standardization of the assessment of diseasespecific QoL with the IPSS BQ will facilitate comparisons of QoL endpoints across different studies.
In conclusion, among men enrolled in the BPH Registry, the IPSS BQ, a disease-specific QoL measure, had a strong positive correlation with the total BPH-II and each of its four questions. These results further support the validity of the IPSS BQ as a convenient tool for assessing disease-specific QoL that can be used in conjunction with the IPSS when determining treatment strategies and evaluating treatment outcomes in men with LUTS/BPH.
